Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.352 Factor de Impacto de 5 años: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v37.i2-6.110
pages 445-461

Cellular Mucins: Targets for Immunotherapy

Vasso Apostolopoulos
The Austin Research Institiute, Studley Road, Heidelberg 3084, Victoria, Australia
Ian F. C. McKenzie
The Austin Research Institiute, Studley Road, Heidelberg 3084, Victoria, Australia

SINOPSIS

Mucins are attracting great interest as potential targets for immunotherapy in the development of vaccines for cancers expressing Mucinl (MUC1) (e.g., breast, pancreas, ovary, and others) as there is (1) a 10-fold increase in the amount in adenocarcinomas; (2) an alteration in expression where they become ubiquitous, and (3) due to altered glycosylation, new epitopes appear on the cell surface that are absent in normal tissues. These new epitopes can be carbohydrate; others are peptide in nature. The cloning of the cDNAs from mucins, particularly MUC1, has led to rapid advances being made, and it is clear that a highly immunogenic peptide exists within the variable number of tandem repeats (VNTR) found in all mucins. This peptide is immunogenic in mice, giving rise to strong antibody production, and most monoclonal antibodies made to breast cancer, which react with the protein core, react with the peptide APDTR. It is now also clear that humans with breast cancer have, in their draining lymph nodes, precursors of cytotoxic T cells that can be stimulated in vitro to react against breast cancer and indeed against the APDTR or a closely related peptide − shown from antibody-blocking studies. These CTLs are unique in that they are non-MHC restricted. The identification of suitable targets, coupled with the known immunogenicity of both the peptide and neo-carbohydrate epitopes, has led to the development of several different programs to immunize humans against breast cancer using either synthetic carbohydrates or peptides conjugated with adjuvants, and clinical trials are now in progress to evaluate their immunogenicity and anti-cancer effects.


Articles with similar content:

Cellular Mucins: Targets for Immunotherapy
Critical Reviews™ in Immunology, Vol.14, 1994, issue 3-4
Vasso Apostolopoulos , Ian F. C. McKenzie
Dendritic Cell-Derived Exosomes as Cell-Free Peptide-Based Vaccines
Critical Reviews™ in Immunology, Vol.25, 2005, issue 3
Julien Taieb, Nathalie Chaput, Laurence Zitvogel
Biology of Granzyme M: A Serine Protease with Unique Features
Critical Reviews™ in Immunology, Vol.29, 2009, issue 4
Pieter J. A. de Koning, Niels Bovenschen, J. Alain Kummer
Peptide Mimotopes as Prototypic Templates of Broad-Spectrum Surrogates of Carbohydrate Antigens for Cancer Vaccination
Critical Reviews™ in Immunology, Vol.27, 2007, issue 3
Gajendra Raghava, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi, Anastas Pashov
DNA Vaccines – A Modern Gimmick or a Boon to Vaccinology?
Critical Reviews™ in Immunology, Vol.37, 2017, issue 2-6
Kevin L. Karem, Barry T. Rouse, Elanchezhiyan Manickan